The COVID-19 pandemic is impacting clinical trials in many ways, not the least of which being the ability for sponsors to continue traditional oversight activities such as on-site clinical trial monitoring. The Association of Clinical Research Organizations (ACRO) has issued recommendations for clinical trial monitoring that will help maintain continuity in clinical trials wherever possible.
In this episode in our Coronavirus Special Edition Series, Paul Colvin, President, Clinical Solutions and Nicole Stansbury, Vice President, Global Clinical Monitoring at Syneos Health, discuss the role of risk-based monitoring and opportunities for remote options that can potentially ensure continuity, trial viability and data preservation through this pandemic and beyond.
Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at [email protected].
* This episode was recorded on 3/26/2020.